<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H77969EF2F69B422597D6BF3BD87D4742" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1231 IH: Research to Accelerate Cures and Equity for Children Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-02-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1231</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170227">February 27, 2017</action-date><action-desc><sponsor name-id="M001157">Mr. McCaul</sponsor> (for himself, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, <cosponsor name-id="D000614">Mr. Duffy</cosponsor>, and <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to establish a program to increase the
			 development of new drugs to treat pediatric cancers, and for other
			 purposes.</official-title></form>
	<legis-body id="H190C7FAF843045CF8E976C48ADF176C4" style="OLC">
 <section id="H21A345CB4676407F9AD2B123D614C149" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Research to Accelerate Cures and Equity for Children Act</short-title></quote> or the <quote><short-title>RACE for Children Act</short-title></quote>.</text> </section><section id="H7FFA57FCB83B4C0A820C2ED91E7FB943"><enum>2.</enum><header>Drug development for pediatric cancer</header> <subsection id="H210C7B7F8AD24F8082F158B2B74A50D0"><enum>(a)</enum><header>Molecular targets regarding cancer drugs</header><text>Section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>) is amended—</text>
 <paragraph id="H9116B92F1AA44820853DD71A861F1EDF"><enum>(1)</enum><text>in subsection (a)(2)(A)(i) by striking <quote>product for the claimed indications in all relevant pediatric subpopulations; and</quote> and inserting</text> <quoted-block display-inline="yes-display-inline" id="H036A6820CC214AC1A8B8CE14F36B9EDE" style="OLC"> <text>product in all relevant pediatric subpopulations—</text><subclause id="HD4A91BE21D484F02A2BEEF8AB3BB56DA"><enum>(I)</enum><text>for the claimed indications; or</text></subclause><subclause id="idBB7637798F8F4413B509051C36A34E99"><enum>(II)</enum><text>for a pediatric cancer indication, if the drug is intended for the treatment of an adult cancer and is directed at a molecular target considered to be germane to the growth and progression of such pediatric cancer; and</text></subclause><after-quoted-block>;</after-quoted-block></quoted-block>
 </paragraph><paragraph display-inline="no-display-inline" id="H2A16A9FEC4E44901A675FC0F9E977D6C"><enum>(2)</enum><text>in subsection (b)(1)—</text> <subparagraph display-inline="no-display-inline" id="HA701D255C8BD41BEBE2E7D2A785D56A2"><enum>(A)</enum><text>by amending subparagraph (A)(i) to read as follows:</text>
						<quoted-block display-inline="no-display-inline" id="H5CAA3EBD2FF64F9A9B6216E939D75B88" style="OLC">
							<subparagraph id="H08911892017F4FD1A8A7F503D8BFD043"><enum>(A)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H25BD267D9CE9423EAB0D4C9B90D62376"><enum>(i)</enum><text>the drug or biological product is used for a substantial number of pediatric patients—</text> <subclause id="H832D0D0C53AC48139A64D09CD9D7A9C4" indent="up1"><enum>(I)</enum><text>for the labeled indications; or</text>
 </subclause><subclause id="HBD244D21489E4664B0E47C9D3CC7B620" indent="up1"><enum>(II)</enum><text>for a pediatric cancer indication, if the drug is intended for the treatment of an adult cancer and is directed at a molecular target considered to be germane to the growth and progression of such pediatric cancer; and</text></subclause></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph display-inline="no-display-inline" id="HECC39D16509F48E79DE40A3C26AB8318"><enum>(B)</enum><text>by amending subparagraph (B) to read as follows:</text> <quoted-block display-inline="no-display-inline" id="H5C912634132447EA90235BEF8A1EDC6F" style="OLC"> <subparagraph id="H21B0A31195184821ACCF18977605C106"><enum>(B)</enum><text>there is reason to believe that the drug or biological product would represent a meaningful therapeutic benefit over existing therapies for pediatric patients—</text>
 <clause id="HB0BED1A97FE64359B6E7FDC5261B09E2"><enum>(i)</enum><text>for one or more of the claimed indications; or</text> </clause><clause id="HB2A9C06E18094CEA8424C901FB8BD5F8"><enum>(ii)</enum><text>for a pediatric cancer indication, if the drug is intended for the treatment of an adult cancer and is directed at a molecular target considered to be germane to the growth and progression of such pediatric cancer; or</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph display-inline="no-display-inline" id="HE8C4B7C7FAAC43BDB1B1FA6C2C95D760"><enum>(3)</enum><text>by amending paragraph (2) of subsection (c) to read as follows:</text> <quoted-block display-inline="no-display-inline" id="H9B81026AC1BB4D38B920C22DB95CA7F8" style="OLC"> <paragraph id="H162A653203D14E21B26FDB41035D992F"><enum>(2)</enum><text>the drug or biological product is in a class of products, is for an indication, or is directed at a specific molecular target in an adult cancer and such molecular target is germane to the growth or progression of cancer in a pediatric cancer, for which there is need for additional options.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection><subsection id="H75F9AFF760134726B3AE27D092222FD4"><enum>(b)</enum><header>Early meeting on pediatric study plan</header>
 <paragraph id="H54D52C632A3E49D2B6F4381425D8A0F6"><enum>(1)</enum><header>In general</header><text>Clause (i) of section 505B(e)(2)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)(2)(C)</external-xref>) is amended to read as follows:</text>
					<quoted-block display-inline="no-display-inline" id="HE85F9FF877144CCAB46030A6A08BDD01" style="OLC">
 <clause id="H432D182CF2B3424AB691C74BDD185990"><enum>(i)</enum><text display-inline="yes-display-inline">shall meet with the applicant—</text> <subclause id="H1D208D6787FF4F63A11DB53DF7FB47BC"><enum>(I)</enum><text display-inline="yes-display-inline">if requested by the applicant with respect to a drug that is intended to treat a serious or life-threatening disease or condition, to discuss preparation of the initial pediatric study plan, not later than the end-of-Phase 1 meeting (as such term is used in section 312.47(b) of title 21, Code of Federal Regulations, or successor regulations) or within 30 days of receipt of such request, whichever is later;</text>
 </subclause><subclause id="H2971E4C0928E4B7EA4334FAAF6E5DC5D"><enum>(II)</enum><text>to discuss the initial pediatric study plan as soon as practicable, but not later than 90 calendar days after the receipt of such plan under subparagraph (A); and</text>
 </subclause><subclause id="HA8B46DF515734C6CB8CD67EFBD829E84"><enum>(III)</enum><text>to discuss any scientific or operational challenges that may be the basis of a deferral under subsection (a)(3) or a full or partial waiver under subsection (a)(4);</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H246B9776A2B6440AAA7A7C2CE1256F51"><enum>(2)</enum><header>Conforming changes</header><text display-inline="yes-display-inline">Section 505B(e) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)</external-xref>) is amended—</text> <subparagraph id="HF56E87C6CAF0493AB2A6F133D7CDA74F"><enum>(A)</enum><text>in the heading of paragraph (2), by striking <quote><header-in-text level="paragraph" style="OLC">meeting</header-in-text></quote> and inserting <quote><header-in-text level="paragraph" style="OLC">meetings</header-in-text></quote>;</text>
 </subparagraph><subparagraph id="H0C2A8B533ED3449C804663D8EA6C5B42"><enum>(B)</enum><text>in the heading of paragraph (2)(C), by striking <quote><header-in-text level="subparagraph" style="OLC">Meeting</header-in-text></quote> and inserting <quote><header-in-text level="subparagraph" style="OLC">Meetings</header-in-text></quote>;</text> </subparagraph><subparagraph id="H306AA3DA3B454E9F98153589A5D20EED"><enum>(C)</enum><text>in clauses (ii) and (iii) of paragraph (2)(C), by striking <quote>no meeting</quote> each place it appears and inserting <quote>no meeting under clause (i)(II)</quote>; and</text>
 </subparagraph><subparagraph id="HF28454E2D3EF4FEA98AF742474A00A1E"><enum>(D)</enum><text>in paragraph (3) by striking <quote>meeting under paragraph (2)(C)(i)</quote> and inserting <quote>meeting under paragraph (2)(C)(i)(II)</quote>.</text> </subparagraph></paragraph></subsection><subsection id="H2AE1F22B937445EA97A67DB219B1448E"><enum>(c)</enum><header>Orphan drugs</header><text>Section 505B(k) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(k)</external-xref>) is amended by inserting <quote>except in the case of a drug or biological product that is intended for the treatment of an adult cancer and is directed at a molecular target considered to be germane to the growth and progression of a pediatric cancer,</quote> after <quote>regulation,</quote>.</text>
 </subsection><subsection id="H07467FCC07A14CA6B1080D0F4FA10972"><enum>(d)</enum><header>Guidance</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue guidance on the implementation of the amendments to section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>) made by this section, including—</text>
 <paragraph id="H04F9B85FA5B74059999900A351D8EEFF"><enum>(1)</enum><text display-inline="yes-display-inline">study designs;</text> </paragraph><paragraph id="H35EA9C1D17AB4446AB2EC3472B6C13AF"><enum>(2)</enum><text display-inline="yes-display-inline">molecular targets considered to be germane to the growth and progression present in one or more cancers in pediatric populations that may be appropriate for assessment under such section 505B, as so amended; and</text>
 </paragraph><paragraph id="HC1BF932924D8467FAD36BAC67611EFA4"><enum>(3)</enum><text>considerations for implementation of such section 505B, as so amended, and waivers of the requirements of such section 505B with regard to molecular targets for which several drugs may be under investigation.</text>
 </paragraph></subsection><subsection id="H50F22ECD42544B9187A843B5311DFC7B"><enum>(e)</enum><header>Applicability</header><text display-inline="yes-display-inline">This section and the amendments made by this section apply with respect to applications for a drug submitted under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) on or after the date that is 18 months after the date of enactment of this Act.</text>
 </subsection><subsection id="H3F7F95E0EB28472CB09C32C16AE142E1"><enum>(f)</enum><header>Report to Congress</header><text>Section 508(b) of the FDA Safety and Innovation Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c-1">21 U.S.C. 355c–1(b)</external-xref>) is amended—</text> <paragraph id="HFCB32CF54BB847259930B9530E7A01AA"><enum>(1)</enum><text>in paragraph (10), by striking <quote>; and</quote> and inserting <quote>;</quote>; and</text>
 </paragraph><paragraph id="H709242AA9AB64D9B9C77751B7DCBC4B2"><enum>(2)</enum><text>by striking paragraph (11) and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="HAF4A73312C134D54AD50E06AE95EFA42" style="OLC"> <paragraph id="H5950E51563C74269B1BCAB17A9D6AC93"><enum>(11)</enum><text>an assessment of the impact of the amendments to such section 505B made by the <short-title>RACE for Children Act</short-title> on pediatric labeling of drugs and pediatric labeling of molecularly targeted drugs for the treatment of cancer;</text>
 </paragraph><paragraph id="HDD918636360A41CFB6BB73622F6E9059"><enum>(12)</enum><text>an assessment of the efforts of the Secretary to implement the plan developed under section 505C–1 of the Federal Food, Drug, and Cosmetic Act, regarding earlier submission of pediatric studies under sections 505A and 505B, including—</text>
 <subparagraph id="H86A156A9E6A9481EAD9B056104A7B982"><enum>(A)</enum><text>the average length of time after the approval of an application under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(1)</external-xref>) before studies conducted pursuant to such sections 505A or 505B are completed, submitted, and incorporated into labeling;</text>
 </subparagraph><subparagraph id="H50A50C7ECDD242EF8389B1248FAEC719"><enum>(B)</enum><text>the average length of time after the receipt of a proposed pediatric study request before the Secretary responds to such request;</text>
 </subparagraph><subparagraph id="H5B4B000DCBB74CF4A2F307E0D539FBB7"><enum>(C)</enum><text>the average length of time after the submission of a proposed pediatric study request before the Secretary issues a written request for such studies;</text>
 </subparagraph><subparagraph id="H25FF4361AF4B4308AD8FC970AA9FD0B3"><enum>(D)</enum><text>the number of written requests issued for each investigational new drug prior to the submission of an application under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act; and</text>
 </subparagraph><subparagraph id="H8388BF276C924569AC73EE37E2995ED2"><enum>(E)</enum><text>the average number, and range of numbers, of amendments to written requests issued;</text> </subparagraph></paragraph><paragraph commented="no" id="H40EA7553E6DF4BB6B3D494E5ED8BF499"><enum>(13)</enum><text>a list of sponsors of applications or holders of approved applications who received exclusivity under such section 505A after receiving a letter issued under such section 505B(d)(1) and before the studies referred to in such letter were completed and submitted; and</text>
 </paragraph><paragraph id="H9D8081C63FA3477EA366697F5BE1C4CF"><enum>(14)</enum><text>a list of assessments required under subsections (a)(2)(A)(i)(II) and (b)(1)(B)(ii) of section 505B.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H7464B7B224F74FF2AC5AD4999B28B8C7"><enum>(g)</enum><header>Rule of construction</header><text>Nothing in this section, including the amendments made by this section, shall limit the authority of the Secretary of Health and Human Services to issue written requests under section 505A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>).</text>
			</subsection></section><section id="H78BC533E47244D47A36AE73251AC3945"><enum>3.</enum><header>Improving the timeliness of pediatric studies</header>
 <subsection id="H13D18AAE6DA8467A8A6B527C52FA7379"><enum>(a)</enum><header>Informing internal review committee</header><text>Section 505A(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a(f)</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H383E20B7D98D4AF4B22C500A3F67DC50" style="OLC">
 <paragraph id="HFFC08F667FAF47F4BE36C9C23B5C4A2A"><enum>(7)</enum><header>Informing internal review committee</header><text>The Secretary shall provide to the committee referred to in paragraph (1) any response issued to an applicant or holder with respect to a proposed pediatric study request.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H4C2006F0CC6842B59F79036F4A3B2EC8"><enum>(b)</enum><header>Action on submissions</header><text>Section 505A(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a(d)</external-xref>) is amended—</text> <paragraph id="H2A9BE38AB4144888967433282D8F51E1"><enum>(1)</enum><text>by redesignating paragraphs (3) through (5) as paragraphs (4) through (6), respectively; and</text>
 </paragraph><paragraph id="HE709A1C534AE427994F99031D37F3BA7"><enum>(2)</enum><text>by inserting after paragraph (2) the following:</text> <quoted-block display-inline="no-display-inline" id="HC376FA34FA114E13B7F92AC8B0842463" style="OLC"> <paragraph id="H767C75FBF3C04D1A94E2514EC9C3FB0D"><enum>(3)</enum><header>Action on submissions</header><text>The Secretary shall review and act upon a submission of a proposed pediatric study request or a sponsor’s proposed amendment to a written request for pediatric studies within 120 days of the submission.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HC83EB9589F8049DC98375E803BB73521"><enum>(c)</enum><header>Study</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the internal review committee established under section 505C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355d">21 U.S.C. 355d</external-xref>) shall, not later than one year after the date of enactment of this Act, develop and implement a plan to achieve, when appropriate, earlier submission of pediatric studies under section 505A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>). Such plan shall include recommendations to achieve—</text>
 <paragraph id="H26D7DCBDE5E3480881E958706EB1F239"><enum>(1)</enum><text display-inline="yes-display-inline">earlier discussion of proposed pediatric study requests and written requests with sponsors, and if appropriate, at the meeting required under section 505B(e)(2)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)(2)(C)</external-xref>), as amended by section 2;</text>
 </paragraph><paragraph id="H2D007B73A9D04FEABF46A9281891B952"><enum>(2)</enum><text display-inline="yes-display-inline">earlier issuance of written requests for a pediatric study under such section 505A, including for investigational new drugs prior to the submission of an application under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(1)</external-xref>); and</text>
 </paragraph><paragraph id="H80931D726F6C4314BBB1AE862F57C953"><enum>(3)</enum><text display-inline="yes-display-inline">shorter timelines, when appropriate, for the completion of studies pursuant to a written request under such section 505A.</text>
 </paragraph></subsection></section><section id="HB142D6A702BD47F6A9F7A55734060008"><enum>4.</enum><header>Neonatology expertise</header><text display-inline="no-display-inline">Section 6(d) of the Best Pharmaceuticals for Children Act (<external-xref legal-doc="usc" parsable-cite="usc/21/393a">21 U.S.C. 393a(d)</external-xref>) is amended by striking <quote>For the 5-year period beginning on the date of enactment of this subsection, at</quote> and inserting <quote>At</quote>.</text>
		</section></legis-body></bill>


